jckrdu,


Ok, Nodded off a bit but got through entire CC. Well, you heard correctly as to what Rabin said... Even if you forget Socius numbers and look at numbers below you would have to buy the fact that 183MM options and warrants went off in the past 2 months. I for one don't buy it. If that happened for example and ALL warrants were exercised, wouldn't you think Rabin would mention the xtra $15MM+ in ACT's treasury? The S-1 info below describes the kind of cash we would have if all were exercised. I realize it was not 192MM as some were cancelled along the way but approx. 140-150MM were still there. So not one outstanding stock option or one outstanding warrant exist? So Lanza's options are all exercised too?(2)Includes 9,616,667 shares subject to stock options that are currently exercisable or exercisable within 60 days of February 7, 2011. And Rabin has no shares backing up his options either? Wonderful I say...:)

(warrant S-1)
This prospectus relates to the public offering of up to 192,148,119 shares of common stock, par value $.001 per share, of Advanced Cell Technology, Inc. (“Common Stock”), by the selling stockholders. These shares are issuable to the selling stockholders upon exercise of warrants which were issued to the selling stockholders in private placements in September 2005, August 2006, August 2007, and March 2008, and were amended and restated on July 29, 2009 (as amended and restated, the “Amended and Restated Warrants”). The Amended and Restated Warrants have an exercise price of $0.10 and a termination date of June 30, 2014.

(warrant S-1)
This prospectus relates to shares of our Common Stock that may be offered and sold from time to time by the selling stockholders. We will not receive any of the proceeds resulting from the sale of Common Stock by the selling stockholders. We will receive the sale price of any Common Stock we sell to the selling stockholders upon exercise of warrants for cash. If all of the warrants the underlying are shares of which are included in this prospectus are exercised for cash, we will receive $19,214,811.90. There is no assurance that any of the warrants will be exercised. We expect to use the proceeds received from the exercise of the warrants, if any, for general working capital purposes.

jckrdu,

(definition)
Fully Diluted Outstanding Shares
The number of shares representing total company ownership, including common shares and current conversion or exercised value of the preferred shares, options, warrants, and other convertible securities.


I was hoping to hear the "fully diluted" statement myself before responding but haven't been able to get CC. Anyway, I don't for a second believe the fully diluted count is the same as OS#. That would mean that ALL options and warrants were exercised since year end(bolded number below) it would also mean no shares are left in the Stock PLAN and nothing is in reserve for Socius financing...Wouldn't it seem strange to you that not even the insiders exercised stock options and very few warrants were exercised when the pps had peaked in December but now we are to believe they were all exercised in past 2 months or so?

____________________________________________________________________

Current OS# 1.507 Billion as of March 11, we know 27.5MM shares were added in Feb. so subtract those out...Do the numbers work for any of you?

(all info below from 10K)
This was the # of OS we had on Dec 31, 2010.. 1,439,826,362

As of December 31, 2010, on an aggregated basis our debt and preferred stock financings may result in being converted into 6,400,425 shares of our common stock, and warrants and options that may be converted into approximately 183,307,361 shares of our common stock.

During the year ended December 31, 2010, the Company received $719,636 upon exercise of warrants into 6,663,300 shares of common stock.

There were no exercises of stock options for the named executive officers in the year ended December 31, 2010.

louisa,


just getting settled in here so I haven't heard the CC. I did see the PR and I am always amazed at the spin put on the pay off of debt as if we have some financial gurus at the helm. Maybe adding that since Sept of 2009 they diluted the bajeebers out of the Company and shareholders to the tune of 1 Billion additional shares would have put things in context?..:) What company couldn't eliminate their debt with that novel approach?...

louisa, I believe ACT has followed the SEC disclosure rules on setting up CC to make public what they choose, jmo.

Compliance and Disclosure Interpretations: Regulation FD Jun 4, 2010

Question 102.01

Question: If an issuer wants to make public disclosure of material nonpublic information under Regulation FD by means of a conference call, what information must the issuer provide in the notice and how far in advance should notice be given?

Answer: An adequate advance notice under Regulation FD must include the date, time, subject matter and call-in information for the conference call. Issuers also should consider the following non-exclusive factors in determining what constitutes adequate advance notice of a conference call:

Timing: Public notice should be provided a reasonable period of time ahead of the conference call. For example, for a quarterly earnings announcement that the issuer makes on a regular basis, notice of several days would be reasonable. We recognize, however, that the period of notice may be shorter when unexpected events occur and the information is critical or time sensitive.

Availability: If a transcript or re-play of the conference call will be available after it has occurred, for instance via the issuer's website, we encourage issuers to indicate in the notice how, and for how long, such a record will be available to the public. [Aug. 14, 2009]
http://www.sec.gov/divisions/corpfin/guidance/regfd-interp.htm

sports guy,



As ACT announced this CC about 10 days ago I am expecting we will hear on 10K(no debt, cash on hand for trials and operating costs etc) and expound as much as possible on clinical trials.( ongoing process with trial site IRB's, contracts signed soon type thing)
Most likely touch on many things that can be viewed in last conference presentation(patents, Myoblast Phase 2, EU Orphan status, etc)
If there is something new and exciting, I for one will welcome it. I don't expect bad news given the fact they announced this CC prior and we have seen the 10K plus timing the CC prior to opening bell. Nothing wrong with CC's and I for one hope they continue the practive for all of the investment community. For those who are unaware, the last conference call transcript can be read at the following link.(a group of shareholders pressured for this CC) http://www.sec.gov/Archives/edgar/data/1140098/000101376209001648/form14a.htm

no Jon, none of the four below were expected or addressed prior to 10K filing.There were 4 of them this time around accounting for almost 48MM shares.

17.15MM to Optimus to pay off debt to prior patent attorneys

3.22MM to Optimus for ACT's inability to issue shares

7.4MM to cancel Transition contract and repay monies received

20MM to Gemini Master Fund for dispute of shares issued via warrants

The S-1 was filed back on Feb 14. Amendment to the S-1 was filed on March 18. Why? As stated prior, the 10K came out March 17 so all the NEW info is required to be added. The SEC cannot and will not declare a registration statement "effective" unless it has the most recent and current info added to prospectus. The SEC does not judge the merits of offering itself. SEC objective is full disclosure of all available info for investors to see. So the amendment filed Friday is just business that ACT is obligated to perform and has nothing to do with CC..

It must be the "super full moon" tonight as I haven't understood much of anything directed at me today. Let's try this.

nmbr1stckpckr, Socius is not the company right now to suggest huge selling. Move one desk over in the same office and gear towards Optimus if you are looking for possibilities and there are others too.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58335104

SteveMQ , I now have seen the post your questions refer to.
That person is referring to shares in recent registration statement "being added" to cause a drop. I can say without hesitation they don't have a clue what they are talking about. I do not make trading predictions and never have.

By the looks of questions in mailbox the last 2 days many are not understanding how these registration filings work or what they are for. The topic has been covered extensively but I will try again if someone here wants.

agree with who and based on what?..eom

not real sure where you are coming from. Socius has no shares that can be sold at this time..

S-1/A filed,

This amendment is to update the Feb 14 S-1 filing(Socius shares)with recent/updated 10K info. The S-1 for Socius has yet to be declared "effective" by the SEC.
http://www.sec.gov/Archives/edgar/data/1140098/000101376211000662/forms1a.htm

me76951,


The reverse split is ONLY a topic of discussion as to one of several ways to deal with the share structure when the time comes. Nothing to date has been mentioned about a reverse from ACT.

"rock, what reasons would the company have for doing a reverse and have they ever done one before? thanks"

ACT asked for and shareholders approved a reverse split in late December of 2007. The catalyst was the upcoming Myoblast Phase 2 trial scheduled to take place around Feb-March of 2008. The Phase 2 never went anywhere coupled with declining share price caused ACT to cancel the reverse split. The same 3 BOD's we have now backed the proposal.

This the range and time frame of proposal:

APPROVAL OF RESTATED CERTIFICATE OF INCORPORATION TO EFFECT REVERSE STOCK SPLIT AT A RATIO WITHIN THE RANGE FROM ONE-FOR-TWO TO ONE-FOR-TEN AT ANY TIME PRIOR TO MAY 1, 2008

(per ACT at the time)
Purpose of the Reverse Stock Split

The purpose of the proposed reverse stock split is to decrease the number of outstanding shares of old common stock in order to increase the market value of each share of the new common stock.

Immediately following a reverse stock split, the per-share price of a company's common stock generally increases proportionately with the reverse stock split ratio. Given the circumstances in which the Company expects to effect the reverse stock split, management believes that the reverse stock split would not only lead to a proportionate increase in the price of the new common stock but would be one in a series of steps that would expand the market for, and increase the price of, the old common stock. Theoretically, decreasing the number of shares of old common stock outstanding should not, by itself, affect the marketability of the shares, the type of investor interested in acquiring them, or the Company's reputation in the financial community. In practice, however, many investors and market makers consider low priced stock as unduly speculative in nature, and, as a matter of policy, avoid investment and trading in such stocks. For instance, institutional investors often have policies limiting their trading in securities to securities that are listed on a national exchange or quoted on a national market and which meet certain price per share criteria. The presence of the foregoing limiting factors may adversely affect not only the pricing of the Company's old common stock but also its trading liquidity and the Company's access to the capital markets. The Company hopes that the decrease in the number of shares of its outstanding common stock resulting from the reverse stock split, and the anticipated increase in the per share trading price, will encourage greater interest in its common stock among members of the financial community and the investing public and possibly create a more liquid market for the Company's stockholders.

One of the primary reasons the Board approved and is recommending the reverse stock split to stockholders is to enable the new common stock to qualify for listing on an exchange or a Nasdaq market. Of the major United States markets, the common stock could most readily qualify for listing on the American Stock Exchange (the "AMEX") and the Nasdaq SmallCap Market (the "SmallCap").
http://www.sec.gov/Archives/edgar/data/1140098/000104746907008940/a2180823zpre14a.htm

mail ?,




Jon, Optimus has received approx. 137MM shares in the last 3 months. Roughly half of that was for Series B financing and the other half for assuming claims of unpaid bills including past rent monies owed, monies due to prior patent attorneys and ACT's inability to previously issue shares of its common stock under the Series B preferred stock warrants

morning louisa,


ACT has only one JV and that is SCRMI. CHA Biotech has 60% ownership
and ACT 40%.
http://www.steminternational.com/about/
If Burrill & Company produced any results, nothing has been announced.

sports,


There are two fronts to the year 2010 activity in todays filing.
On the first front we see much of the same ol' crap we have seen for years. Massive share issuance, claims of debt being settled by Optimus or someone else, huge insider compensation and so on and so on...I have bellyached about this stuff plenty so I won't go into detail again. This has to change now with a new page being turned toward the future.

The second front shows plenty too. CD holders are all but gone and mostly debt free. (which cost the Company and shareholders plenty.)We were once again issued an unqualified opinion by the auditors and have two trials cleared by the FDA with other activity planned as well.

So, we had a boatload of "ugly" in the filing but there is also quite a bit of "pretty". 2011 needs to be the year when the ugly disappears and trials pave the path to the potential pretty. ACT's business plan is all about the trials, make no doubt about that. Trial progression with positive results will transform how these filings look and will present opportunities that will benefit all.

I do not feel ACT's market potential will be possible on the OTC with a boatload of shares. To time a move to a big board exchange by the start of trial(s) is the way to go, imo. I realize many here feel we can grow into the shares and predict $20-$100 pps, I honestly don't believe that will happen. I firmly believe that being in position on another exchange either prior or during trials will have the most bang for shareholders and the Company and provide the type of investors that see ACT as a growth stock as well as provide much stronger exposure to the entire investment community, jmo...if you have specific questions sports guy, let me know...

I will repeat what my thoughts have been for some time now. I think we can all agree that something has to be done at some point. When it will happen I am not sure because the bulk of the Socius shares registerd have not been issued and while Socius is certainly aware of situation any amendment or deal could be arranged between the two. Socius contract does state 90 days to correct authorized but how set in stone that is remain to be seen. If a Proxy were to come forward sooner than later I can envision the following proposals as it covers most options ACT would have.

1)Ask for increase in stock option plan shares
2)Increase authorized shares(what number I don't know)
3)ask for approval of revere stock split, with a range, that is good for a certain amount of time to implement)

The above would enable ACT to increase shares and stay OTC, or possibly enact the reverse to meet listing requirements for big board exchange at some time if this scenario presents itself...All IMO..

well, I have seen and heard that same scenario many times over the years so I don't go by what is said but rather what is done. In late November the $10MM available was said to be enough for trials too but soon came another $25MM. Kind of akin to when we voted to authorize 1.75 Billion shares and everyone here said "we will never use them all it was a poison pill strategy"..lol


"Rabin has stated publically for many months now in the corporate presentation. He specifically states that the cash they have on hand and their ability to access more (referring to Socius) will likely not be needed"

morning rumit,


RE:Conference Call

I can only throw some thoughts your way on this topic. The major theme,imo, will be the clinical trials update. I am not sure any revelations will come in that regard but I believe it is important for ACT to do so. I would suggest they will speak to cash on hand, no debt etc also. IMO, if in fact a PRE14A(proxy) is upcoming it would be an appropriate time to address whatever their intentions are. There could be other items like new CEO or something we are unaware of too. We will know soon enough..

ACT has $15MM approx. in cash which is a drop in a bucket as to what they will need to complete 2 trials and possibly start another in Europe. They doubled their employees recently and will be burning through cash at a much faster pace than ever before once trials begin. To think Socius financing won't be needed would be a major stretch, imo.

no, not worried as this situation has been discussed here for the past 6 months and was expected to be an issue. This is addressed by,

a)increasing the authorized shares
b)reverse split
c)share buyback(very remote,imo)
d)both a and b

jckrdu,


The diluted number is over the authorized amount of 1.75 Billion

all #'s are approx.

OS# 1.507 Billion

# of shares to be kept in reserve
options and warrants exercisable 183MM
Socius shares to back up the 25MM financing 224MM

Total OS# plus diluted number (can be exercised)

1.914 Billion

sports,

I will at some point today..thanks

that is a rehash of original PR of sites that are "currently under consideration"

Advanced Cell Technology to Host Conference Call to Discuss 2010 Year-end Financial Results & Provide Corporate Update on Mon...
Advanced Cell Tech (OTCBB:ACTC)
Intraday Stock Chart
Today : Thursday 17 March 2011
Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, announced today that it will hold a conference call on Monday, March 21st at 9 a.m. eastern time during which it will discuss 2010 fourth quarter and year-end results and provide a corporate update.

Interested parties should dial 1-800-931-6358 (domestically) or (212)231-2900 (internationally). A replay of the call will be available for two weeks and can be accessed by dialing 1-800-633-8284 (domestically) or 1(402)977-9140 (internationally), using passcode 21515792.

The call will also be available live by webcast at ACT's website at: http://advancedcell.com/

SETTLEMENT AGREEMENT AND MUTUAL RELEASE

WHEREAS, Gemini Master Fund, Ltd ("Gemini") entered into certain agreements with Advanced Cell Technology, Inc. ("Advanced Cell") entitling Gemini to receive common stock purchase warrants exercisable into shares of Advanced Cell common stock (the "Warrants"); and

A.Advanced Cell shall deliver to Gemini an aggregate of 20,000,000 shares of Advanced Cell common stock (the "Shares"), issuable upon cashless exercise of all Warrants issued by Advanced Cell to Gemini. This Agreement hereby constitutes such cashless exercise by Gemini, and the Company agrees that no further notices or actions by Gemini are required. The Company represents and warrants that all the Shares are freely tradable and without restriction pursuant to Rule 144. All the Shares shall be electronically delivered to the following account of Gemini by DWAC within 48 hours following the date hereof
http://www.sec.gov/Archives/edgar/data/1140098/000101376211000631/ex10149.htm

10K Notables, part 2

Net loss for 2010 $ (54,373,332 )

As of December 31, 2010, we have $15,889,409 in cash, under $1 million in debt, and $4,636,302 in working capital. During 2010, we received the following amounts:


· $977,917 from a federal grant under the Patient Protection and Affordable Care Act of 2010 (“PPACA”);

· $580,165 upon the sale of our Series A-1 preferred stock;

· Approximately $9.5 million through the sale of 1,000 shares of our Series B preferred stock;

· $4 million through the sale of our Series C preferred stock;

· $5,880,000 through the sale of convertible notes; and

· $1,685,000 upon the second close of our 2009 debenture.

We plan to fund our operations for the next twelve months primarily from the following financings:
· As of December 31, 2010, $1,581,834 is available to us upon the sale of our Series A-1 preferred stock for a maximum placement commitment of $5 million.
· As of December 31, 2010, $21 million is available to us upon the sale of our Series C preferred stock for a maximum placement commitment of $25 million.
· We continue to repay our debt financings in shares of common stock, enabling us to use our cash resources to fund our operations.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Advanced Cell Technology, Inc. and subsidiary’s internal control over financial reporting as of December 31, 2010, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 16, 2011 expressed an unqualified opinion on the effectiveness of Advanced Cell Technologies, Inc. and subsidiary’s internal control over financial reporting.

Warrants Exercisable, December 31, 2010 134,931,242
Options Outstanding..48,376,119

On December 20, 2010, Optimus purchased a claim previously brought to the Company in connection with indebtedness to Ropes and Gray LLP for legal services performed between May 2007 and January 2010. On December 21, 2010, Optimus and the Company settled the claim in the full amount of indebtedness, including legal fees, for $2,486,256. During December 2010, the Company issued 17,146,254 shares of its common stock to Optimus in full settlement of this claim. The legal services received from Ropes and Gray LLP had been accrued during the years 2007-2010, in the periods in which these expenses were incurred. The amount due to Ropes and Gray for their services was $2,386,278, and the Company recognized the additional $99,978 as legal expenses during the year ended December 31, 2010. This settlement ended all claims previously brought to the Company by Ropes and Gray LLP, and Optimus as bona fide claimant.

In December 2010, the Company settled a claim brought against it by Optimus related to the Company’s inability to previously issue shares of its common stock under the Series B preferred stock warrants. The Company and Optimus settled on the issuance of shares of the Company’s common stock to Optimus worth $654,000, which was recognized in financing costs in the Company’s consolidated statements of operations during the year ended December 31, 2010. The Company is required to issue 3,222,786 to Optimus to settle this claim in full.

The Board of Directors held one meeting in 2010. All board members were present at the meeting.

With respect to the cash bonus awarded to Dr. Lanza in 2010, $146,875 was awarded. The Board approved the award of $100,000 as a bonus because this was the amount that the Board thought was fair in light of Mr. Lanza’s recent contributions to the Company and one that he would also find acceptable. The balance of the bonus awarded to Dr. Lanza was awarded to him as part of the bonuses awarded to all employees that participated in the filing of the IND application multiplied by 1.5, which equaled $46,875.

Option Exercises and Stock Vested
There were no exercises of stock options for the named executive officers in the year ended December 31, 2010. During 2010, Mr. Caldwell was issued 85,325,595 shares of restricted stock with a one year restriction. During 2010, Mr. Lanza was issued 20,000,000 shares of stock which vested immediately.

Beneficial Ownership of Directors
Directors and Executive Officers as a Group ( 5 Persons) 158,896,720 10.38 %

10K Notables, part 1

As of December 31, 2010, on an aggregated basis our debt and preferred stock financings may result in being converted into 6,400,425 shares of our common stock, and warrants and options that may be converted into approximately 183,307,361 shares of our common stock.

On February 9, 2011, we entered into a settlement agreement and mutual release with Transition Holdings Ltd. (“Transition”), in a dispute over the $3,500,000 received in 2008 and 2009. The two parties disputed the nature of the consideration provided to the Company. We agreed to deliver Transition 7,413,000 shares of our common stock, issuable in consideration of all monies previously delivered to the Company by Transition in the aggregate amount of $3,500,000. Upon issuance of the shares, all other agreements between the Company and Transition, including licenses, are deemed cancelled, null and void, and of no force or effect.

On February 11, 2011, we entered into a settlement agreement and mutual release with Gemini Master Fund, Ltd. (“Gemini”). The two parties disputed the number of shares of common stock to be issued upon exercise of warrants held by Gemini. In settlement, we agreed to deliver Gemini 20,000,000 shares of its common stock, issuable upon cashless exercise of all warrants previously issued by the Company to Gemini. Upon issuance of the shares to Gemini, all other agreements between the Company and Gemini, including any agreements between the Company and any entity controlled by Gemini or their principals, are hereby deemed cancelled, null and void, and of no force or effect.

As of March 11, 2011, there were approximately 235 shareholders of record of our common stock.

During the year ended December 31, 2010, the Company issued 31,399,587 shares of its common stock in a cashless exercise of warrants. These shares were eligible for sale under the Rule 144.

The Phase I/II trial will be a prospective, open-label study that is designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation to patients with advanced SMD. A total of twelve patients will be enrolled in the study at multiple clinical sites. The sites which are currently under consideration are the Jules Stein Eye Institute at UCLA (headed by Dr. Steven Schwartz); the Casey Eye Institute in Portland, Oregon (headed by Dr. Peter Francis of the Oregon Health Sciences University); the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts (headed by Dr. Shalesh Kaushal, Chair of the Department of Ophthalmology); the UMDNJ – New Jersey Medical School in Newark, New Jersey (headed by Dr. Marco Zarbin, Chair, Institute of Ophthalmology and Visual Science); additional sites may be considered.

General and administrative expenses for 2010 compared to 2009 increased by $12,067,106 to $15,506,191 in 2010. This expense increase was primarily a result of shares of our stock issued to our Chief Executive Officer and directors, and stock options issued to employees, for a total increase in G&A salaries, bonuses and option compensation of $10.8 million. Further, legal fees were higher in 2010 because we retained council to defend the Company in legal matters (see “Commitments and Contingencies” footnote to our accompanying consolidated financial statements, as well as the “Legal Proceedings” section filed in this Form 10-K).

On December 22, 2010, Optimus CGII, Ltd. (“Optimus”) purchased a claim previously brought against the Company in a civil action by Alexandria Real Estate-79/96 Charlestown Navy Yard (“ARE”). In that action, ARE alleged that it was unable to relet the premises and therefore seeking rent for the vacated premises since September 2008. ARE also sought certain clean-up and storage expenses. On December 23, 2010, Optimus and the Company settled the claim in the amount of $8,000,167. During December 2010, we issued 55,688,368 shares of the Company’s common stock to Optimus in full settlement of this claim. Accordingly, we recognized loss on settlement in the amount of $8,000,167 in our accompanying consolidated statements of operations for the year ended December 31, 2010. This settlement ended all claims previously brought against the Company by ARE, and Optimus as bona fide claimant.

NT-10K filed and the 10K,

The number of outstanding shares of the registrant’s Common Stock, $0.001 par value, was 1,506,715,382 shares as of March 11, 2011.

Folks, no need to send mail asking what the reason for filing delay is because I don't know. There are MANY reasons that could be. The first that popped into my mind was the fact CEO Caldwell transacted everything except the last 17 days of December. Auditors need verifications on everything they ask for and it can be a big chore sometimes if the person running the show isn't around. It could be as simple as that or more complex like restatements or anywhere inbetween. As stated before, ACT will have to state the reason in the NT-10K when filed...

No, The current EDGAR system hours of operation for submitting EDGARized documents electronically are 6:00 a.m.-10:00 p.m. Eastern Time, weekdays, excluding Federal holidays. Files submitted and accepted by EDGAR before 5:30 p.m. Eastern Time will have the current business day's date. Section 16 filings as well as certain other filings will have the current business day's date if submitted and accepted by 10:00 p.m. Eastern.
http://www.secfile.net/file_process.htm

That is not the case anymore as you can view from this link,
ACT's last delinquency was this.
NT 10-Q Documents Notification of inability to timely file Form 10-Q or 10-QSB 2008-05-16

http://www.otcbb.com/DailyListContent/delistings/OTCBB_Eligibility_Status_Report.pdf

The 10K filing was not filed on time so I would suggest we will see a NT-10K filed within 24 hours stating the reason for delay under Rule 12b-25. The extension will grant ACT 15 days to file.
http://taft.law.uc.edu/CCL/34ActRls/rule12b-25.html

IMO, they were possibly aware of this when the PR'd on March 9 thus the language "" later this month in conjunction with the filing of its Form 10-K" as I suggested earlier today..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61006947

We were an accelerated filer on Feb 14 when they filed the S-1, I don't see how that could have changed so due date was today.

post from early in 2010,

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47902562

ACT has been an "accelerated filer" for the past year. Here are the differences.

http://taft.law.uc.edu/CCL/34ActRls/rule12b-2.html

the $21MM is the remaining dollars from $25MM Socius deal secured at year end.

2011 Milestones
1Q
•
Designation for hESC-derived RPE Cells for Stargardt’s Disease

2Q
•
Sign clinical trial agreements for SMD and Dry AMD sites
•
Commence patient selection
•
Treat first patients for SMD and Dry AMD Phase I/II clinical trials
•
Secure European EMA “Orphan” approval for SMD program
•
File with European Medicines Agency (EMA) for RPE program

2ndHalf of 2011
•
Treat additional cohorts of patients in RPE Phase I/II trials
•
Early look at data from first cohort of patients in RPE Phase I/II trials
•
Secure approval from EMA for RPE Program
•
Continue partnering and licensing discussions
•
Advance toward IND filing for hemangioblast program

louisa,


fwiw, the verbage seems odd to me. They PR'd on March 9 knowing the 10K is due one week later and yet they used the phrase " later this month in conjunction with the filing of its Form 10-K" Another fwiw, if ACT files for an extension of 10K they have an additional 15 days. I guess technically the PR verbage is correct, just struck me as odd..Hopefully the 10K will be on track for today..

"ACT plans to update investors on its clinical trial progress when it holds a conference call for the investment community later this month in conjunction with the filing of its Form 10-K with the Securities and Exchange Commission."

Companies may request a filing extension for their Form 10-Q's and 10-K's by submitting Form 12b-25 via the EDGAR system. By filing this form, a filer may gain up to 5 additional days to file Form 10-Q or 15 days to file Form 10-K. Companies have up to 24 hours after the original filing deadline to file Form 12b-25.

MillerTime,


not much "insight" to it, poster bballer answered correctly, no trials have started yet. Welcome to the board.

yes we will. For the person that asked, the 10K is deemed on time if filed by 5:30 ET tomorrow.

Accelerated Filers:
10-K: for Fiscal Year Ended 12/31/10 due Wednesday, March 16, 2011

The EDGAR system hours of operation for submitting files are 6:00 a.m. to 10:00 p.m. Eastern Time, weekdays, excluding Federal Holidays. Files submitted after 5:30 p.m. Eastern (with the exception of Section 16 filings) will receive the next business day's filing date.